#1 Clinical Trials Search in Europe

Gskvx000000008885

Clinical trials are underway to evaluate the safety, efficacy, and immune response of GSKVX000000008885, a novel therapeutic vaccine for chronic hepatitis B (CHB). This vaccine is being tested in combination with other treatments in patients who are already on nucleos(t)ide analogue (NA) therapy. The trials aim to assess the potential of this vaccine to improve outcomes for CHB patients by targeting the hepatitis B virus (HBV) and boosting the immune response against it.

Table of Contents

Overview of GSKVX000000008885

GSKVX000000008885 is an innovative therapeutic vaccine being developed for the treatment of chronic hepatitis B (CHB). This experimental medication is part of a new class of treatments aimed at helping patients who are already on nucleos(t)ide analogue (NA) therapy for CHB[1]. The drug is being studied as a potential way to improve outcomes for people living with this persistent viral infection.

Mechanism of Action

GSKVX000000008885 is designed to work as an immunotherapy, meaning it aims to stimulate the body’s own immune system to fight against the hepatitis B virus (HBV). It is part of a combination approach that includes:

  • Viral vector vaccines: These use modified viruses to deliver HBV-specific genetic material to cells, potentially triggering an immune response against the virus[1].
  • Adjuvanted protein vaccines: These contain HBV proteins along with substances called adjuvants that help boost the immune response[1].

Treatment Approach

The treatment strategy being investigated involves a prime-boost schedule. This means patients receive different types of vaccines in a specific sequence to potentially enhance the immune response against HBV. The approach includes:

  1. Initial “priming” with a viral vector vaccine (ChAd155-hIi-HBV)
  2. “Boosting” with another viral vector vaccine (MVA-HBV)
  3. Additional doses of an adjuvanted protein vaccine (HBc-HBs/AS01B-4)[1]

This combination approach is being tested in patients who are already taking NA therapy to suppress the hepatitis B virus.

Efficacy and Potential Benefits

While research is ongoing, the potential benefits being investigated for GSKVX000000008885 include:

  • Reduction in hepatitis B surface antigen (HBsAg) levels: This is a key marker of HBV infection. A significant decrease could indicate better control of the virus[1].
  • HBsAg loss: Complete loss of this antigen is considered a major treatment goal[1].
  • Improved immune response against HBV: The treatment aims to stimulate both antibody production and T-cell responses specific to hepatitis B[1].

Safety Profile

As with any new treatment, safety is a primary concern. The ongoing clinical trials are closely monitoring for:

  • Injection site reactions (such as redness, pain, and swelling)[2]
  • Systemic side effects
  • Any serious adverse events
  • Changes in laboratory values (blood tests)
  • Potential immune-mediated disorders[2]

It’s important to note that the full safety profile of GSKVX000000008885 is still being established through clinical research.

Ongoing Research

GSKVX000000008885 is currently being studied in clinical trials to determine its safety and effectiveness. These trials are investigating:

  • Different dosing regimens and combinations with other treatments
  • The drug’s ability to produce a sustained virologic response (SVR), which means undetectable levels of HBV over time[2]
  • Long-term safety and efficacy
  • The potential for GSKVX000000008885 to be part of a cure strategy for chronic hepatitis B

Patients interested in learning more about this experimental treatment should discuss with their healthcare provider whether participating in a clinical trial might be appropriate for their situation.

Aspect Details
Study Type Phase I/II clinical trials
Participants Adults (18-65 years) with chronic hepatitis B on stable NA therapy
Intervention GSKVX000000008885 (therapeutic vaccine) in combination with other treatments
Primary Objectives Assess safety, efficacy, and immune response
Key Endpoints HBsAg reduction, HBsAg loss, immune response markers
Administration Intramuscular injection
Duration Variable, up to several months of treatment and follow-up

FAQ

  • What is GSKVX000000008885? GSKVX000000008885 is an investigational therapeutic vaccine being developed to treat chronic hepatitis B. It is designed to stimulate the immune system to fight against the hepatitis B virus in patients who are already on antiviral therapy.
  • Who is eligible to participate in these clinical trials? Generally, adults aged 18-65 with chronic hepatitis B who are stable on nucleos(t)ide analogue therapy are eligible. Specific criteria include having HBV DNA levels below 90 IU/mL and HBsAg levels above 100 IU/mL. Patients should not have cirrhosis or other significant liver conditions.
  • How is the vaccine administered? The vaccine is administered as an intramuscular injection. The exact dosing schedule varies depending on the specific trial protocol, but it may involve multiple doses over several weeks or months.
  • What are the main goals of these clinical trials? The main goals are to assess the safety of the vaccine, evaluate its ability to stimulate an immune response against HBV, and determine its efficacy in reducing hepatitis B surface antigen (HBsAg) levels or achieving HBsAg loss in patients.
  • What are the potential benefits of this new vaccine? If successful, this vaccine could potentially help chronic hepatitis B patients achieve better control of the virus, reduce HBsAg levels, or even achieve functional cure. It may offer a new treatment option for patients who have not responded adequately to current therapies.

Ongoing Clinical Trials on Gskvx000000008885

  • Study on the Safety and Effectiveness of GSKVX000000008866 and GSKVX000000009151 in Adults with Chronic Hepatitis B on Nucleotide Analogue Therapy

    Not recruiting

    1
    Investigated drugs:
    Belgium Germany Spain

  • Study on Safety and Efficacy of Bepirovirsen and Drug Combination for Chronic Hepatitis B in Patients on Nucleos(t)ide Analogue Therapy

    Not recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria France Germany Italy Poland +2

Glossary

  • Chronic Hepatitis B (CHB): A long-lasting liver infection caused by the hepatitis B virus that can lead to serious liver damage if left untreated.
  • Nucleos(t)ide analogue (NA) therapy: A type of antiviral medication used to suppress hepatitis B virus replication in patients with chronic hepatitis B.
  • HBsAg (Hepatitis B surface antigen): A protein on the surface of the hepatitis B virus that is detectable in the blood and indicates active hepatitis B infection.
  • HBeAg (Hepatitis B e antigen): A protein produced by the hepatitis B virus that is associated with high levels of virus replication.
  • Immunogenicity: The ability of a substance, such as a vaccine, to provoke an immune response in the body.
  • Efficacy: The ability of a treatment to produce the desired result under ideal circumstances.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Serious Adverse Event (SAE): An adverse event that results in death, is life-threatening, requires hospitalization, or causes significant disability.
  • Sustained Virologic Response (SVR): A measure of treatment success in hepatitis, typically defined as undetectable virus levels for a specific period after completing treatment.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-gskvx000000008866-and-gskvx000000009151-in-adults-with-chronic-hepatitis-b-on-nucleotide-analogue-therapy/
  2. http://clinicaltrials.eu/trial/study-on-safety-and-efficacy-of-bepirovirsen-and-drug-combination-for-chronic-hepatitis-b-in-patients-on-nucleostide-analogue-therapy/